Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA)

This study has been completed.
Sponsor:
Information provided by:
Santen Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01411254
First received: August 4, 2011
Last updated: July 17, 2014
Last verified: July 2014

August 4, 2011
July 17, 2014
Not Provided
Not Provided
Best Corrected Visual Acuity(BCVA)
Change from baseline of Best Corrected Visual Acuity(BCVA) in ETDRS letter score
Same as current
Complete list of historical versions of study NCT01411254 on ClinicalTrials.gov Archive Site
retinal thickness
Change in retinal thickness from baseline
Same as current
Not Provided
Not Provided
 
Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA)
A Randomized, Multicenter, Sham Controlled, Double-Masked, Phase 2/3 Study Assessing Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema

This study will evaluate the efficacy and safety of Betamethasone Microsphere (DE-102) for diabetic macular edema.

Not Provided
Interventional
Phase 2
Phase 3
Not Provided
Diabetic Macular Edema
  • Drug: Betamethasone Microsphere (DE-102) Low Dose
  • Drug: Betamethasone Microsphere (DE-102) High Dose
  • Drug: Sham
  • Experimental: 1
    Intervention: Drug: Betamethasone Microsphere (DE-102) Low Dose
  • Experimental: 2
    Intervention: Drug: Betamethasone Microsphere (DE-102) High Dose
  • Sham Comparator: 3
    Intervention: Drug: Sham
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Provided signed, written informed consent
  • 20 years of age or older with diabetic macular edema

Exclusion Criteria:

  • Active proliferative diabetic retinopathies (PDR) in the study eye
  • Uncontrolled diabetes mellitus and hypertension
  • Known steroid-responder
Both
20 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT01411254
01021103
Not Provided
Not Provided
Santen Pharmaceutical Co., Ltd.
Not Provided
Not Provided
Santen Pharmaceutical Co., Ltd.
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP